Touyun Biotech Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Amy Ha
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3yrs |
| CEO ownership | n/a |
| Management average tenure | 5.5yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%
Sep 15
Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jul 17Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%
Apr 22Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?
Apr 08What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You
Feb 07Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding
Dec 18Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt
Sep 19Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)
Jul 28Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Sep 13Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt
May 18Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Dec 24Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?
Mar 12If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns
Jan 15
The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares
Jan 15How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?
Dec 11CEO
Amy Ha (52 yo)
3yrs
Tenure
Ms. Amy Ha (Former name: Ha Man) is Chief Executive Officer of Touyun Biotech Group Limited from January 03, 2022. She has extensive experiences in the financial management and investment. From April 1998...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.3yrs | HK$3.60m | 27.35% HK$ 148.1m | |
| Executive Director | 8.1yrs | HK$1.22m | no data | |
| Chief Executive Officer | 3yrs | no data | no data | |
| Company Secretary | 2.4yrs | no data | no data |
5.5yrs
Average Tenure
41.5yo
Average Age
Experienced Management: 1332's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.3yrs | HK$3.60m | 27.35% HK$ 148.1m | |
| Executive Director | 8.1yrs | HK$1.22m | no data | |
| Independent Non-Executive Director | 10.2yrs | HK$248.00k | no data | |
| Independent Non-Executive Director | 10.2yrs | HK$248.00k | no data | |
| Independent Non-Executive Director | 9.4yrs | HK$248.00k | no data | |
| Non-Executive Director | 8.1yrs | HK$240.00k | no data | |
| Independent Non-Executive Director | 4.2yrs | HK$100.00k | no data | |
| Non-Executive Director | 4.8yrs | HK$120.00k | 5.2% HK$ 28.1m | |
| Non-Executive Director | 4.2yrs | HK$978.00k | no data | |
| Non-Executive Director | 4.2yrs | HK$20.00k | 0.036% HK$ 193.0k |
8.1yrs
Average Tenure
44.5yo
Average Age
Experienced Board: 1332's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:30 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Touyun Biotech Group Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|